Lv C, Fang W, Wu N, Jiao W, et al. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage
II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase
2b trial. Lung Cancer 2023;178:151-156.
PMID: 36863124